- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05004194
Vestibular Caloric Stimulation and the Modulation of Pain in Fibromyalgia
Vestibular Caloric Stimulation and the Modulation of Pain in Fibromyalgia: An Open Label Pilot Study
The management of chronic pains is challenging and fraught with limitations. Fibromyalgia is a common pain disorder characterized by chronic widespread pains, associated with fatigue and impaired quality of life. Fibromyalgia affects millions of people and is among the most common reasons for consulting with a rheumatologist. The food and drug administration (FDA) approved three medications to treat fibromyalgia, though there are many patients for whom these medications are ineffective, poorly tolerated or cost-prohibitive. Accordingly, there exists a need for novel therapeutics.
The researchers would like to test the therapeutic efficacy of a non-pharmacologic non-interventional bedside technique called vestibular caloric stimulation (VCS). VCS, irrigating the external ear canal with water, is a simple, non-invasive, cost-free procedure with preliminary data suggesting potential for improving pain. VCS is a form of neuromodulation and there are anatomically defined pathways elucidated to help explain how this works. There currently exists limited data on the topic, only case reports and case series. Given a clear need for additional therapeutics in many patients with fibromyalgia, the researchers have elected to conduct this trial.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10029
- Icahn School of Medicine at Mount Sinai
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- At least 18 years old with ability to comprehend and consent to protocol.
- Diagnosis of fibromyalgia by American College of Rheumatology (ACR) criteria (questionnaire).
- At least a 4/10 baseline on the visual analogue pain scale (VAS).
- Stable fibromyalgia medications for at least 4 weeks.
- Owns or has access to a smart phone or computer to complete outcome measures.
Exclusion Criteria:
- Use of opioids
- Otitis externa or media within the past six months.
- Current ear pain with or without other symptoms of otitis externa.
- History of tympanic membrane rupture or surgery.
- Current pregnancy.
- Inability to lay supine for 30 minutes.
- Limited decision making capacity.
- Engaged in litigation, currently or prior, related to FMS.
- Inability to commute to clinic once.
- Primary language not English.
- Clinically significant or unstable medical or psychological conditions that, in the opinion of the investigator, would compromise participation in the study
- Treatment with the medication meclizine for vertigo
- History of seizures
- Diagnosis of bipolar disorder (treated or untreated)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Cold water caloric stimulation
50 cc of ice-cold water irrigation into the right ear at 1-2 cc/second, once per participant.
|
Irrigation of the right external ear canal
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Change in Numeric Rating Scale (NRS)
Periodo de tiempo: baseline and 1 week after VCS
|
Change in average diary pain scores assessed by daily report on a 11 point numeric rating scale at 1 week after VCS as compared to baseline.
Full scale range from 0-10, higher score indicates more pain.
|
baseline and 1 week after VCS
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Acute change in NRS
Periodo de tiempo: baseline and 5, 15 and 30 minutes after VCS
|
Acute effect of VCS assessed by acute change in pain scores post VCS 5, 15 and 30 minutes post irrigation compared to baseline.
Full scale range from 0-10, higher score indicates more pain.
|
baseline and 5, 15 and 30 minutes after VCS
|
|
Percentage of participants with NRS pain scores >= to 30% and 50%
Periodo de tiempo: 30 minutes, 24 hours, 1 week, 2 weeks after VCS
|
Percentage of patients with change in pain assessed by NRS pain scores > or equal to 30% and 50%.
|
30 minutes, 24 hours, 1 week, 2 weeks after VCS
|
|
Patient Global Impression of Change (PGIC)
Periodo de tiempo: at 1 weeks, 2 weeks and 4 weeks after VCS
|
Full score from 0-7, with higher score indicating more improvement.
|
at 1 weeks, 2 weeks and 4 weeks after VCS
|
|
Change in Multidimensional Assessment of Fatigue (MAF)
Periodo de tiempo: baseline and at 1, 2 and 4 weeks after VCS
|
MAF is a 16 item instrument, full scale from 0-50, with higher score indicating more fatigue.
|
baseline and at 1, 2 and 4 weeks after VCS
|
|
Michigan Neuropathy Screening Instrument (MNSI)
Periodo de tiempo: baseline and at 1, 2 and 4 weeks after VCS
|
15 "yes or no" questions - full score from 0-13, with higher score indicating more neuropathic symptoms.
|
baseline and at 1, 2 and 4 weeks after VCS
|
|
Change in Brief Pain Inventory Short Form 36 (BPI SF36)
Periodo de tiempo: baseline and at 24 hours, 1 week, 2 weeks, 4 weeks after VCS
|
A 9-item instrument with total score from 0 to 10, with higher score indicating worse outcomes.
Will exclude question 2 which is a diagram and question 7 which asks about medications.
|
baseline and at 24 hours, 1 week, 2 weeks, 4 weeks after VCS
|
|
Change in Fibromyalgia Impact Questionnaire (FIQ)
Periodo de tiempo: baseline and at 1, 2 and 4 weeks after VCS
|
Full scale from 0-100, with higher score indicating a greater impact of fibromyalgia syndrome.
|
baseline and at 1, 2 and 4 weeks after VCS
|
|
Change in Numeric Rating Scale (NRS) for pain in different regions of the body
Periodo de tiempo: baseline and at 24 hours, 1 week, 2 week, 4 week after VCS
|
Pain measured on a numeric rating scale in different regions of the body: the left upper extremity, right upper extremity, left lower extremity, right lower extremity, front of torso, back of torso, head/neck.
Full scale range from 0-10, higher score indicates more pain.
|
baseline and at 24 hours, 1 week, 2 week, 4 week after VCS
|
|
VCS Tolerability Survey
Periodo de tiempo: 24 hours post VCS
|
A seventeen question tolerability instrument developed specifically for caloric stimulation to assess tolerability by measuring the frequency and intensity of headaches, nausea, and vertigo.
the tolerability scale does not have a total score just individual questions re headache nausea vertigo discomfort and grades intensities rated on a 0-10 scale, higher numbers reflecting higher severity of symptoms.
|
24 hours post VCS
|
|
Number of participants willing to trial VCS again
Periodo de tiempo: 24 hours post VCS
|
Number of participants expressing willingness to trial VCS again
|
24 hours post VCS
|
|
Change in Subjective Overall Well Being Scale
Periodo de tiempo: at baseline and at 30 minutes after VCS, 24 hours, 1 week, 2 week and 4 weeks after VCS relative
|
Subjective Overall Well Being Scale is a 11 point scale with full scale from 0-10, with higher score reflecting the best possible overall subjective disposition
|
at baseline and at 30 minutes after VCS, 24 hours, 1 week, 2 week and 4 weeks after VCS relative
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Ioannis Tassiulas, MD, Icahn School of Medicine at Mount Sinai
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- GCO 20-2730
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .